• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconweight-loss and diet control industry

weight-loss and diet control industry

Page 5 of 10
After testing new drug compounds that appear to mimic the physical benefits of exercise in rodents, scientists say a pill may someday be able to do the same in humans.
LifeAn exercise pill may soon offer the same benefits as a workout, scientists say
By Lindsey LeakeMarch 18, 2024
Oprah Winfrey
FinanceWeightWatchers, reeling from collapsing stock and Oprah’s departure in the age of Ozempic, vows to ‘prove the naysayers wrong’ and turn its fortunes around
By Amanda GerutMarch 14, 2024
Catherine Howarth, CEO of ShareAction.
RetailRebel investors want KitKat maker Nestlé to cut back on junk food—but the fortunes of its Mindful Chef brand suggest customers aren’t ready for a health kick
By Ryan HoggMarch 14, 2024
A person using Ozempic
RetailWegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By Ashleigh Furlong and BloombergMarch 13, 2024
LifeDoes the GOLO Diet work? Experts explain the pros, cons, and risks
By Amanda LoudinMarch 9, 2024
tube of wegovy injections
LifestyleNovo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 
By Prarthana PrakashMarch 8, 2024
Health62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
By Jonel Aleccia and The Associated PressMarch 7, 2024
WHO
HealthA billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
Oprah Winfrey
LeadershipOprah to leave WeightWatchers board, donating her stake over ‘perceived conflict of interest around her taking weight loss medications’
By Amanda GerutFebruary 28, 2024
BOXES OF WEGOVY DRUGS
LifestyleNovo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
RetailNovo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
RetailNovo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By Prarthana PrakashFebruary 5, 2024
LifeAmericans spend an average of $5,300 a year on wellness. From biohacking to walking retreats, here are the top 10 trends driving the market
By Alexa MikhailFebruary 2, 2024
RetailNovo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
Eli Lilly and Company says its popular drugs Mounjaro and Zepbound, also known as GLP-1s, are not meant for those without obesity or type 2 diabetes.
HealthEli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
1...
  • 3
  • 4
  • 5
  • 6
  • 7
...10
Most Popular
Magazine
The youngest-ever female CEO of a Fortune 500 company is fighting Trump's cuts to keep Medicaid strongAn image of a popular article
By Fortune EditorsMarch 24, 2026
Commentary
The Treasury just declared the U.S. insolvent. The media missed itAn image of a popular article
By Fortune EditorsMarch 23, 2026
Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers — ‘or you’re neurodivergent’An image of a popular article
By Fortune EditorsMarch 24, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.